MOLN Relative Valuation
MOLN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MOLN is overvalued; if below, it's undervalued.
Historical Valuation
Molecular Partners AG (MOLN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.02. The fair price of Molecular Partners AG (MOLN) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：4.45
Fair
-3.29
PE
1Y
3Y
5Y
Trailing
Forward
-0.68
EV/EBITDA
Molecular Partners AG. (MOLN) has a current EV/EBITDA of -0.68. The 5-year average EV/EBITDA is 2.98. The thresholds are as follows: Strongly Undervalued below -62.42, Undervalued between -62.42 and -29.72, Fairly Valued between 35.68 and -29.72, Overvalued between 35.68 and 68.38, and Strongly Overvalued above 68.38. The current Forward EV/EBITDA of -0.68 falls within the Historic Trend Line -Fairly Valued range.
-0.40
EV/EBIT
Molecular Partners AG. (MOLN) has a current EV/EBIT of -0.40. The 5-year average EV/EBIT is -0.87. The thresholds are as follows: Strongly Undervalued below -10.59, Undervalued between -10.59 and -5.73, Fairly Valued between 3.99 and -5.73, Overvalued between 3.99 and 8.85, and Strongly Overvalued above 8.85. The current Forward EV/EBIT of -0.40 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Molecular Partners AG. (MOLN) has a current PS of 0.00. The 5-year average PS is 29.25. The thresholds are as follows: Strongly Undervalued below -56.27, Undervalued between -56.27 and -13.51, Fairly Valued between 72.01 and -13.51, Overvalued between 72.01 and 114.77, and Strongly Overvalued above 114.77. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-4.61
P/OCF
Molecular Partners AG. (MOLN) has a current P/OCF of -4.61. The 5-year average P/OCF is -2.42. The thresholds are as follows: Strongly Undervalued below -15.65, Undervalued between -15.65 and -9.04, Fairly Valued between 4.19 and -9.04, Overvalued between 4.19 and 10.81, and Strongly Overvalued above 10.81. The current Forward P/OCF of -4.61 falls within the Historic Trend Line -Fairly Valued range.
-2.28
P/FCF
Molecular Partners AG. (MOLN) has a current P/FCF of -2.28. The 5-year average P/FCF is -1.44. The thresholds are as follows: Strongly Undervalued below -19.72, Undervalued between -19.72 and -10.58, Fairly Valued between 7.70 and -10.58, Overvalued between 7.70 and 16.84, and Strongly Overvalued above 16.84. The current Forward P/FCF of -2.28 falls within the Historic Trend Line -Fairly Valued range.
Molecular Partners AG (MOLN) has a current Price-to-Book (P/B) ratio of 1.39. Compared to its 3-year average P/B ratio of 0.92 , the current P/B ratio is approximately 51.89% higher. Relative to its 5-year average P/B ratio of 2.10, the current P/B ratio is about -33.71% higher. Molecular Partners AG (MOLN) has a Forward Free Cash Flow (FCF) yield of approximately -44.99%. Compared to its 3-year average FCF yield of -32.15%, the current FCF yield is approximately 39.94% lower. Relative to its 5-year average FCF yield of -15.06% , the current FCF yield is about 198.73% lower.
1.42
P/B
Median3y
0.92
Median5y
2.10
-43.43
FCF Yield
Median3y
-32.15
Median5y
-15.06
Competitors Valuation Multiple
The average P/S ratio for MOLN's competitors is 0.00, providing a benchmark for relative valuation. Molecular Partners AG Corp (MOLN) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MOLN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MOLN in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Molecular Partners AG (MOLN) currently overvalued or undervalued?
What is Molecular Partners AG (MOLN) fair value?
How does MOLN's valuation metrics compare to the industry average?
What is the current P/B ratio for Molecular Partners AG (MOLN) as of Dec 05 2025?
What is the current FCF Yield for Molecular Partners AG (MOLN) as of Dec 05 2025?
What is the current Forward P/E ratio for Molecular Partners AG (MOLN) as of Dec 05 2025?